
NASDAQ:CRMD
This summary was created by AI, based on 2 opinions in the last 12 months.
CorMedix Inc. (CRMD-Q) has garnered attention from analysts due to its innovative antimicrobial catheter lock product that has demonstrated significant effectiveness in reducing infections by over 70%. Despite its potential, the stock has experienced a downturn of 25.7%, prompting a recommendation to cover the position. Analysts highlight the stock's solid fundamentals, including a price-to-earnings ratio of 17x and a robust return on equity of 38%. A stop-loss has been advised at $9.50, while the target price represents a potential upside to $17.00, aligning with a higher analysts’ price target of $19.50. The company appears to be making strides in the healthcare market, though investors are urged to remain cautious amid volatility.
CorMedix Inc. is a American stock, trading under the symbol CRMD (previously CRMD-Q on Stockchase) on the NASDAQ (CRMD). It is usually referred to as NASDAQ:CRMD or CRMD
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on CRMD (previously CRMD-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for CorMedix Inc..
CorMedix Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-25. Read the latest stock experts ratings for CorMedix Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for CorMedix Inc..
CorMedix Inc. is covered by Stockchase experts and is worth watching.
On 2026-09-03, CorMedix Inc. (CRMD) stock closed at a price of $8.47.
Our PAST TOP PICK with CRMD has triggered its stop at $9.50. To remain disciplined, we recommend covering the position at this time.